Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Published:
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, AMD, AT&T, Broadcom, Energy Transfer, Ford, Fortinet, Intel, Intelsat, Shake Shack and T-Mobile.
Published:
Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.
Published:
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AT&T, Facebook, T-Mobile and the other most prominent earnings reports due this week.
Published:
Last Updated:
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Here are 20 companies that should offer investors who are retired or near retirement some added income to help make their golden years safe and sound.
Published:
Last Updated:
Allergan has finally announced that its shareholders have voted to approve the company’s acquisition of AbbVie. The acquisition is expected to close in early 2020, but it is still subject to...
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
The week of September 28 saw many analyst upgrades and positive calls in blue-chip stocks. Here are six that received very favorable analyst coverage with above-consensus upside projections.
Published:
Last Updated:
These four top large-cap pharmaceutical stocks for investors to consider all pay solid dividends and look like very solid fourth-quarter ideas.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Boston Beer, Carvana, HD Supply, Marathon Petroleum, Square, Trade Desk and Whirlpool.
Published:
Last Updated: